Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2026 04:56 ET | Source: Research and Markets

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Genome Editing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
January 15, 2026 11:08 ET | Source: Research and Markets

Genetic Modification Therapies Set to Surge, Market Valued at $32.1 Billion by 2030

Dublin, Jan. 15, 2026 (GLOBE NEWSWIRE) -- The "Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing" has been...
January 12, 2026 08:30 ET | Source: Metagenomi, Inc.

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook

Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
December 03, 2025 04:07 ET | Source: Research and Markets

Gene Editing Collaboration and Licensing Deals Trends Report 2025: Comprehensive Listing of 384 Gene Editing Deals Announced Since 2016

Dublin, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive...
December 01, 2025 09:56 ET | Source: Research and Markets

Gene Editing Technology Trends and Forecast Report 2025: A $10+ Billion Market by 2030, Driven by Technological Advancements, Personalized Medicine Demand, and Rising Genetic & Chronic Disease Burden

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Gene Editing Technologies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
December 01, 2025 07:00 ET | Source: Metagenomi, Inc.

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
November 19, 2025 06:18 ET | Source: Cellectis Inc.

Cellectis publie un article dans Nature Communications sur un procédé d’édition génomique non viral efficace pour l’insertion génique dans les cellules souches hématopoïétiques

NEW YORK, 19 nov. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome...
November 19, 2025 06:18 ET | Source: Cellectis Inc.

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
November 17, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

Pluristyx and Breakthrough T1D partner to engineer an immune-cloaked, safety-enabled iPSC line to advance universal islet therapies for type 1 diabetes.
November 10, 2025 07:25 ET | Source: Dyadic International, Inc.

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics